$CELC has been mentioned 26 times over the past 12 months across 2 distinct FinTwit voices, with the first mention occurring on July 23, 2025. The biotech-focused discussion is dominated by @jacobplieth, who accounts for 23 of the mentions, while @adamfeuerstein contributes 3 mentions. The most recent activity occurred on June 3, 2026, with discussions centering on clinical trial data and conference presentations.

Recent conversation among these voices has focused on Celcuity's clinical trial outcomes, particularly comparing median progression-free survival (mPFS) results between different dosing approaches and trial cohorts. @jacobplieth noted that the company's phase 1b trial showed 14.6-month mPFS in mutant cases, or 19.7 months with intermittent dosing, and analyzed how the Viktoria-1 trial results compared to these benchmarks. @adamfeuerstein reported on ASCO conference scheduling, indicating that $CELC presentations were scheduled for Tuesday as late-breaker sessions.